AE Wealth Management LLC Has $3.88 Million Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

AE Wealth Management LLC raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 16.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,957 shares of the company’s stock after purchasing an additional 1,134 shares during the quarter. AE Wealth Management LLC’s holdings in IDEXX Laboratories were worth $3,877,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. Riverview Trust Co purchased a new position in IDEXX Laboratories during the first quarter worth about $26,000. Crewe Advisors LLC bought a new position in shares of IDEXX Laboratories during the 1st quarter worth approximately $26,000. Ridgewood Investments LLC purchased a new position in shares of IDEXX Laboratories in the 2nd quarter worth approximately $27,000. Institutional & Family Asset Management LLC bought a new position in shares of IDEXX Laboratories in the second quarter valued at approximately $28,000. Finally, DSM Capital Partners LLC purchased a new stake in shares of IDEXX Laboratories during the fourth quarter valued at approximately $33,000. Institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. Piper Sandler cut their price target on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a report on Wednesday, August 14th. Stifel Nicolaus decreased their price objective on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a report on Monday, June 24th. Finally, BTIG Research assumed coverage on shares of IDEXX Laboratories in a research report on Thursday, July 25th. They issued a “buy” rating and a $580.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $582.25.

IDEXX Laboratories Trading Down 2.0 %

Shares of IDEXX Laboratories stock opened at $506.74 on Monday. The stock has a market capitalization of $41.85 billion, a P/E ratio of 49.06, a P/E/G ratio of 4.17 and a beta of 1.33. IDEXX Laboratories, Inc. has a 52-week low of $372.50 and a 52-week high of $583.39. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.03 and a current ratio of 1.37. The stock’s 50-day simple moving average is $483.85 and its 200 day simple moving average is $498.74.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $2.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.88 by ($0.44). The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.01 billion. IDEXX Laboratories had a net margin of 22.34% and a return on equity of 57.03%. The business’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same period last year, the firm earned $2.67 EPS. As a group, research analysts anticipate that IDEXX Laboratories, Inc. will post 10.45 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.